{"entity":{"id":"nct07444437","kind":"trial","name":"A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer","aka":[],"tldr":"A phase 2 trial of LM103 TILs Injection in non-small-cell lung cancer, run by Suzhou BlueHorse Therapeutics Co., Ltd., now recruiting.","summary":"A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT07444437 by Suzhou BlueHorse Therapeutics Co., Ltd., with 45 participants planned, started 2026-02-26 and due to reach its primary completion in 2027-12-31. Interventions recorded: LM103 TILs Injection and PD-1 / PD-L1 monoclonal antibody.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07444437","url":"https://clinicaltrials.gov/study/NCT07444437"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07444437","phase":"2","setting":"A Multicenter, Randomized, Controlled, Open-label, Phase IIa Trial on Autologous Tumor Infiltrating Lymphocyte Injection (LM103 TILs) for the Adjuvant Treatment of Non-small Cell Lung Cancer With Negative Driver Gene Mutations","sponsor":"Suzhou BlueHorse Therapeutics Co., Ltd.","enrolled":45,"outcomes":[]},"route":"/trials/nct07444437/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}]}}